Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 <i>Diabetes Mellitus</i> Predicted by 3D QSAR Pharmacophore Models, Molecular Docking and <i>De Novo</i> Evolution
Dipeptidyl peptidase-IV (DPP-IV) rapidly breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Thus, the use of DPP-IV inhibitors to retard the degradation of endogenous GLP-1 is a possible mode of therapy correcting the defect in incre...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-08-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/24/16/2870 |